SB-265610

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameSB-265610
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-8 receptors antagonistsC-X-C motif chemokine receptor 2 antagonists
TargetsInterleukin-8 receptorsC-X-C motif chemokine receptor 2
Therapy Area/IndicationsInflammatory Bowel Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsInflammatory Bowel Diseases

Other Information

ATC CodeN/A
Related LinksN/A